

Application No.: 09/816,839
Attorney Docket No.: TNX 00-04
Customer No.: 26839

20. (NEW) An antibody that binds to C2a or the C2a portion of C2, or a C2a binding fragment thereof, which inhibits both the classical and the lectin complement pathways at a molar ratio of about 1:2 (antibody to C2).
21. (NEW) An antibody that binds to the same epitope as the monoclonal antibody 175-62 and inhibits at a molar ratio of about 1:2 (antibody to C2).
22. (NEW) The antibody of claim 19, wherein the antibody fragment is a Fab, F(ab')₂, Fv or single chain Fv.
23. (NEW) The antibody of claim 19, wherein the antibody is monoclonal.
24. (NEW) The monoclonal antibody of claim 23, wherein the antibody is a chimeric, deimmunized, humanized or a human antibody.
25. (NEW) A monoclonal antibody 175-62.
26. (NEW) A cell line that produces the monoclonal antibody 175-62.
27. (NEW) A pharmaceutical composition comprising the antibody of claim 19 and a pharmacologically acceptable carrier, excipient, stabilizer, or diluent.
28. (NEW) A method of inhibiting complement activation comprising administering an antibody that binds C2a or the C2a portion of C2.
29. (NEW) A method of inhibiting the classical and lectin complement pathways comprising administering an antibody that binds C2a or the C2a portion of C2.
30. (NEW) The method of claim 28, wherein the inhibition of complement activation is determined *in vitro*.
31. (NEW) The method of claim 28, wherein the molar ratio of antibody to C2 is less than or equal to 1:2.

Application No.: 09/816,839
Attorney Docket No.: TNX 00-04
Customer No.: 26839

32. (NEW) A method of treating a disease or condition that is mediated by excessive or uncontrolled activation of the complement system comprising administering, *in vivo* or *ex vivo*, the antibody of any one of claims 19, 20 or 21.
33. (NEW) The method of claim 32, wherein the antibody is administered by intravenous infusion, intravenous bolus injection, intraperitoneal, intradermal, intramuscular, subcutaneous, intranasal, intratracheal, intraspinal, intracranial, or orally.
34. (NEW) A diagnostic method comprising the detection of the amount of C2 or C2a present in a sample with the antibody of claim 19.
35. (NEW) The diagnostic method of claim 34, wherein the antibody is the monoclonal antibody 175-62. —

B5
Cancel

REMARKS

Applicants hereby cancel claims 1-18 without prejudice or disclaimer to the subject matter contained therein. Applicants reserve the right to file continuation applications directed to this subject matter.

Applicants have added claims 19-35 to expedite prosecution. Support for these claims can be found in the specification as a whole, page 7 and in claims 1-18, specifically. No new matter has been introduced by these amendments. Although claims 28-35 are directed to subject matter that has been withdrawn from consideration, Applicants request that these claims be entered because Applicants intend to rejoin the subject matter of these claims upon finding of allowable subject matter.